Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,205

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

March 30, 2020

Study Completion Date

March 30, 2020

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

V114

15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.

BIOLOGICAL

Prevnar 13®

13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.

Trial Locations (30)

100

National Taiwan University Hospital ( Site 0500), Taipei

704

National Cheng Kung University Hospital ( Site 0501), Dawan

22911

Charlottesville Medical Research Center, LLC ( Site 1003), Charlottesville

23606

Health Research of Hampton Roads, Inc. ( Site 1007), Newport News

28223

Hospital Universitario Quiron Madrid ( Site 0304), Pozuelo de Alarcón

33012

Indago Research & Health Center, Inc ( Site 1002), Hialeah

33014

Lakes Research LLC ( Site 1005), Miami Lakes

33024

Research Centers of America, LLC ( Site 1014), Hollywood

33174

Advanced Medical Research Institute ( Site 0117), Miami

44122

Rapid Medical Research, Inc. ( Site 1011), Cleveland

67114

Alliance for Multispecialty Research, LLC ( Site 1008), Newton

78229

Diagnostics Research Group ( Site 1000), San Antonio

Synexus ( Site 1009), San Antonio

84109

J Lewis Research Inc / Foothill Family Clinic ( Site 1013), Salt Lake City

85206

Synexus ( Site 1001), Mesa

89104

Wake Research Clinical Research Center of Nevada, LLC ( Site 1010), Las Vegas

92103

Artemis Institute for Clinical Research ( Site 1012), San Diego

B2N 1L2

Colchester Research Group ( Site 2002), Truro

N5W 6A2

Milestone Research ( Site 2003), London

N7T 4X3

Bluewater Clinical Research Group Inc ( Site 2004), Sarnia

M9W 4L6

Manna Research Inc.. ( Site 2007), Toronto

H9R 3J1

Dynamik Research ( Site 2000), Pointe-Claire

J1J 2G2

Q & T Research Sherbrooke Inc. ( Site 2001), Sherbrooke

192-0071

P-One Clinic, Keikokai Medical Corp. ( Site 0400), Hachiōji

812-0025

Souseikai PS Clinic ( Site 0402), Fukuoka

861-4157

Souseikai Nishikumamoto Hospital ( Site 0404), Kumamoto

532-0003

Medical Corporation Heishinkai OPHAC Hospital ( Site 0401), Osaka

171-0014

Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 0403), Tokyo

03004

Instituto de Ciencias Medicas - ICM ( Site 0300), Alicante

08540

CAP Centelles ( Site 0301), Centelles

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03950622 - Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) | Biotech Hunter | Biotech Hunter